



Advanced Strategies in the Care of Hepatocellular Carcinoma Patients

Guest Editors:

Prof. Dr. Matteo Donadon

Department of Surgery,
University Maggiore Hospital,
Corso Mazzini 18, 28100 Novara,
Italy

Prof. Dr. Guido Torzilli

Director of Department of
Surgery, Division of Hepatobiliary
Surgery & General Surgery,
Humanitas Research Hospital,
20089 Rozzano, Italy

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

Dear Colleagues,

We are honored to be the Guest Editors of this Special Issue of *Cancers* that summarizes current research in the diagnosis and treatment of hepatocellular carcinoma (HCC). HCC is the most common primary liver cancer, with geographical variations among its prevalence. With HCC still being the leading cause of death in patients with cirrhosis, and considering the worldwide increasing incidence in patients with underlying metabolic associated liver disease, working on HCC should be one of the research priorities. In this Special Issue, we welcome papers that enhance our knowledge of innovative diagnostic and prognostic methods and discuss the results of therapeutic experimentation, including those focused on translational research.

We look forward to receiving your contributions.

Prof. Dr. Matteo Donadon

Prof. Dr. Guido Torzilli

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
 [@Cancers_MDPI](https://twitter.com/Cancers_MDPI)